Sep 2025 $17 M Private placement after listing $10 to $50 million 13
AcelRx Pharmaceuticals Inc.: Private sale, Sep 2025 × Investors in this round 13 investors had bought by the notice of Sep 15, 2025: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $17 M of $29 M offered; $12 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Badri P Dasu · Executive Officer Raffi P Asadorian · Executive Officer Shakil P Aslam · Executive Officer Vincent J Angotti · Executive Officer, Director Abhinav J Jain · Director Adrian P Adams · Director Jill P Broadfoot · Director Marina P Bozilenko · Director Mark J Wan · Director Stephen J Hoffman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Raffi Asadorian, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 15, 2025. Read the notice at the SEC .
equity, options SEC Apr 2025 $5 M Private placement after listing $2 to $10 million 11
AcelRx Pharmaceuticals Inc.: Private sale, Apr 2025 × Investors in this round 11 investors had bought by the notice of Apr 17, 2025: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $15 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $1,050,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Badri P Dasu · Executive Officer Raffi P Asadorian · Executive Officer Shakil P Aslam · Executive Officer Vincent J Angotti · Executive Officer, Director Abhinav J Jain · Director Adrian P Adams · Director Jill P Broadfoot · Director Marina P Bozilenko · Director Mark J Wan · Director Stephen J Hoffman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round A.G.P./Alliance Global Partners (CRD 8361) · New York, New York Sold in all US states BTIG, LLC (CRD 122225) · San Francisco, California Sold in all US states Signed by Raffi Asadorian, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 17, 2025. Read the notice at the SEC .
equity, options SEC Jan 2024 $6 M Private placement after listing $2 to $10 million 6
AcelRx Pharmaceuticals Inc.: Private sale, Jan 2024 × Investors in this round 6 investors had bought by the notice of Jan 29, 2024: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Badri B Dasu · Executive Officer Pamela P Palmer · Executive Officer, Director Raffi P Asadorian · Executive Officer Vincent J Angotti · Executive Officer, Director Abhinav B Jain · Director Adrian P Adams · Director Howard B Rosen · Director Jill P Broadfoot · Director Marina P Bozilenko · Director Mark B Wan · Director Richard P Afable · Director Stephen J Hoffman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Raffi Asadorian, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 29, 2024. Read the notice at the SEC .
options SEC Jul 2023 $10 M Private placement after listing $10 to $50 million 10
AcelRx Pharmaceuticals Inc.: Private sale, Jul 2023 × Investors in this round 10 investors had bought by the notice of Jul 28, 2023: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $625,001
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Raffi P. Asadorian · Executive Officer Vincent J. Angotti · Executive Officer, Director Adrian P. Adams · Director Howard B. Rosen · Director Jill P. Broadfoot · Director Marina P. Bozilenko · Director Mark B. Wan · Director Pamela P. Palmer · Director Richard P. Afable · Director Stephen J. Hoffman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in CT, IL, NC, NV, NY, and outside the US Signed by Raffi Asadorian, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 28, 2023. Read the notice at the SEC .
equity, options SEC Jan 2022 $5 M Private placement after listing $2 to $10 million 32
AcelRx Pharmaceuticals Inc.: Private sale, Jan 2022 × Investors in this round 32 investors had bought by the notice of Jan 24, 2022: 28 accredited, 4 not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $6 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Badri Dasu · Executive Officer Pamela Palmer · Executive Officer, Director Raffi Asadorian · Executive Officer Vincent Angotti · Executive Officer, Director Adrian Adams · Director Howard Rosen · Director Jill Broadfoot · Director Marina Bozilenko · Director Mark Edwards · Director Mark Wan · Director Richard Afable · Director Stephen Hoffman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Raffi Asadorian, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 24, 2022. Read the notice at the SEC .
equity SEC Jun 2012 $10 M Private placement after listing $10 to $50 million 10
AcelRx Pharmaceuticals Inc.: Private sale, Jun 2012 × Investors in this round 10 investors had bought by the notice of Jun 7, 2012: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $625,000
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks finders' fees as estimates
The company Corporation, incorporated in Delaware People named in the notice Anil Dasu · Executive Officer James Welch · Executive Officer Larry Hamel · Executive Officer Pamela Palmer · Executive Officer, Director Richard King · Executive Officer, Director Guy Nohra · Director Howie Rosen · Director Mark Edwards · Director Mark Wan · Director Stephen Hoffman · Director Thomas Schreck · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Common Stock; Warrants to purchase Common Stock; Common Stock issuable upon exercise of Warrants”On the use of proceeds: “The proceeds will be used for general corporate purposes.”Signed by Mark B. Weeks, Secretary. Source: SEC Form D, newest notice filed Jun 7, 2012. Read the notice at the SEC .
equity, options SEC Jun 2011 $21 M No. 3 $10 to $50 million 2
AcelRx Pharmaceuticals Inc.: Raise no. 3, Jun 2011 × Investors in this round 2 investors had bought by the notice of Jul 13, 2011: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $21 M of $21 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Badri N. Dasu · Executive Officer Hamel G. Lawrence · Executive Officer James H. Welch · Executive Officer Pamela P. Palmer · Executive Officer Richard King · Executive Officer, Director Guy J. Nohra · Director Howard B. Rosen · Director Mark B. Wan · Director Stephen J. Hoffman · Director Thomas H. Schreck · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Promissory Notes in which $3,000,000 dollars of which can be converted into Company Common Stock at a fixed conversion price of $5.73; Warrants to purchase Common Stock and Common Stock issuable upon exercise of Warrants and conversion of Promissory Notes”On the use of proceeds: “Proceeds will be used for the ARX-01 Phase 3 clinical trial in addition to the general business purposes.”Signed by James H. Welch, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 13, 2011. Read the notice at the SEC .
debt, options SEC Sep 2010 $8 M No. 2 $2 to $10 million 8
AcelRx Pharmaceuticals Inc.: Raise no. 2, Sep 2010 × Investors in this round 8 investors had bought by the notice of Sep 21, 2010: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $12 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Anil Dasu · Executive Officer Carter King · Executive Officer Larry Hamel · Executive Officer Linda Judge · Executive Officer Pamela Palmer · Executive Officer, Director Richard King · Executive Officer, Director Guy Nohra · Director Howie Rosen · Director Mark Wan · Director Stephen Hoffman · Director Thomas Schreck · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Promissory Notes convertible into Preferred Stock; Warrants to purchase Preferred Stock”On the use of proceeds: “The proceeds will be used for general corporate purposes.”Signed by Mark B. Weeks, Secretary. Source: SEC Form D, newest notice filed Sep 21, 2010. Read the notice at the SEC .
debt, options SEC Nov 2009 $15 M No. 1 $10 to $50 million 8
AcelRx Pharmaceuticals Inc.: Raise no. 1, Nov 2009 × Investors in this round 8 investors had bought by the notice of Nov 25, 2009: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for AcelRx Pharmaceuticals Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $15 M of $30 M offered; $15 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Anil A Dasu · Executive Officer Carter A King · Executive Officer Larry A Hamel · Executive Officer Linda A Judge · Executive Officer Mark B Weeks · Executive Officer Pamela A Palmer · Executive Officer, Director Thomas A Schreck · Executive Officer, Director Guy B Nohra · Director Howie B Rosen · Director Mark B Wan · Director Steve B Sullivan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “The proceeds will be used for general corporate purposes.”Signed by Mark B. Weeks, Secretary. Source: SEC Form D, newest notice filed Nov 25, 2009. Read the notice at the SEC .
equity SEC